Alliance Of Wound Care Stakeholders Inc

The alliance shaped policy development in 2024 as we: -led advocacy urging fda to withdraw its proposal to reclassify hundreds of antimicrobial wound products to class iii, a policy shift that would result in the unnecessary removal of many important products from the market and challenge quality care. -escalated concerns with the episode-based cost measure being developed for non-pressure ulcers via a series of letters, comments and conversations flagging flaws in the field testing and the many ways the measure did not accurately capture the data necessary for a fair, reliable, accurate measure. -urged cms to enable payment for clinicians to measure and fit lymphedema compression garments via an ongoing advocacy initiative of letters, comments and meetings to keep focus on this issue.-gained advisory panel on hospital outpatient payment support of the alliance's recommendation to fix flawed total contact casting payment with a separately payable apc code for tcc when performed on the same date of service as a debridement and/or the application of ctp removing a barrier that inconveniences patients and providers by preventing these treatments from being performed on the same date of service.-pursued update to dmemac lcd to establish coverage of topical oxygen therapy for diabetic foot ulcer.-proactively advanced ctp payment methodology recommendations focused on asp pricing as cms continues to internally consider and vet its payment approach to this category of products across sites of care. -maintained focus the important role of real-world evidence in wound care research and the importance of fda/cms dialogue to move forward. -submitted 32 comments to regulators and legislators elevating the visibility, voice and influence of the wound care community in policy development